ImmunoPrecise Antibodies Q4 2023 Earnings Report

ImmunoPrecise Antibodies EPS Results

• Actual EPS: -$0.15
• Consensus EPS: -$0.12
• Beat/Miss: Missed by -$0.03
• One Year Ago EPS: N/A

ImmunoPrecise Antibodies Revenue Results

• Actual Revenue: $4.15 million
• Expected Revenue: $4.45 million
• Beat/Miss: Missed by -$300.00 thousand
• YoY Revenue Growth: N/A

ImmunoPrecise Antibodies Announcement Details

• Quarter: Q4 2023
• Date: 7/10/2023
• Time: N/A

ImmunoPrecise Antibodies (NASDAQ:IPA), together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.